JP2002519318A5 - - Google Patents

Download PDF

Info

Publication number
JP2002519318A5
JP2002519318A5 JP2000556766A JP2000556766A JP2002519318A5 JP 2002519318 A5 JP2002519318 A5 JP 2002519318A5 JP 2000556766 A JP2000556766 A JP 2000556766A JP 2000556766 A JP2000556766 A JP 2000556766A JP 2002519318 A5 JP2002519318 A5 JP 2002519318A5
Authority
JP
Japan
Prior art keywords
corticosteroid
weight
surfactant component
high hlb
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000556766A
Other languages
English (en)
Other versions
JP2002519318A (ja
JP4875239B2 (ja
Filing date
Publication date
Priority claimed from US09/105,838 external-priority patent/US6241969B1/en
Application filed filed Critical
Publication of JP2002519318A publication Critical patent/JP2002519318A/ja
Publication of JP2002519318A5 publication Critical patent/JP2002519318A5/ja
Application granted granted Critical
Publication of JP4875239B2 publication Critical patent/JP4875239B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Description

【特許請求の範囲】
【請求項１】 （ａ）溶解形態のコルチコステロイド約５μｇ／ｍｌ〜約５ｍｇ／ｍｌ、
（ｂ）高ＨＬＢ界面活性剤成分において存在する界面活性剤のＨＬＢが約１０を超えていて、そして高ＨＬＢ界面活性剤成分が、ビタミンＥのエトキシル化誘導体少なくとも５０重量％を含有する、製薬学的に許容しうる高ＨＬＢ界面活性剤成分約０．１〜約２０重量％、および
（ｃ）水相少なくとも約７０重量％：
から本質的になる、治療用量のコルチコステロイドを呼吸器に投与するために適当な組成物。
【請求項２】 （ａ）溶解形態のコルチコステロイド約５μｇ／ｍｌ〜約５ｍｇ／ｍｌ、
（ｂ）高ＨＬＢ界面活性剤成分において存在する界面活性剤のＨＬＢが約１０を超えていて、そして高ＨＬＢ界面活性剤成分が、ビタミンＥのエトキシル化誘導体少なくとも５０重量％を含有する、高ＨＬＢ界面活性剤成分約０．１〜約２０重量％、および
（ｃ）水相少なくとも約７０重量％：
を含んでなる、治療用量のコルチコステロイドを呼吸器に投与するために適当な組成物。
【請求項３】 （ａ）（１）溶解形態のコルチコステロイド５μｇ／ｍｌ〜約５ｍｇ／ｍｌ、（２）高ＨＬＢ界面活性剤成分において存在する界面活性剤のＨＬＢが約１０を超えていて、そして高ＨＬＢ界面活性剤成分が、ビタミンＥのエトキシル化誘導体少なくとも５０重量％を含有する、高ＨＬＢ界面活性剤成分約０．１〜約２０重量％、および（３）水相少なくとも約７０重量％、を含んでなるコルチコステロイド組成物を提供すること；
（ｂ）コルチコステロイド組成物をエアゾル化すること；および
（ｃ）吸入によってコルチコステロイド組成物のエアゾルの治療に有効な用量を投与すること：
を含む、治療用量のコルチコステロイドを呼吸器に投与する方法。
【請求項４】 （ａ）（１）溶解形態のコルチコステロイド約５０μｇ／ｍｌ〜約１０ｍｇ／ｍｌ、（２）高ＨＬＢ界面活性剤成分において存在する界面活性剤のＨＬＢが約１０を超えていて、そして高ＨＬＢ界面活性剤成分が、ビタミンＥのエトキシル化誘導体少なくとも５０重量％を含有する、高ＨＬＢ界面活性剤成分約０．１〜約２０重量％、および（３）水相少なくとも約７０重量％、を含んでなるコルチコステロイド組成物を提供すること；
（ｂ）鼻吸入によってコルチコステロイド組成物の治療に有効な用量を投与すること：
を含む、治療用量のコルチコステロイドを鼻通路に投与する方法。
【請求項５】 （ａ）高ＨＬＢ界面活性剤成分において存在する界面活性剤のＨＬＢが約１０を超えていて、そして高ＨＬＢ界面活性剤成分が、ビタミンＥのエトキシル化誘導体少なくとも５０重量％を含有する、融解された製薬学的に許容しうる高ＨＬＢ界面活性剤成分中に、コルチコステロイド化合物を溶解すること；
（ｂ）続いて、溶解されたコルチコステロイドを含有する融解高ＨＬＢ界面活性剤成分を水相と混合すること：を含み、
この場合、水相が少なくとも約７０重量％量で存在し、そして高ＨＬＢ界面活性剤成分が、希釈コルチコステロイド組成物の約０．１〜約２０重量％量で存在する、
溶解形態のコルチコステロイドを含有する希釈コルチコステロイド組成物の製造方法。
JP2000556766A 1998-06-26 1999-06-24 鼻および肺送達のためのコルチコステロイドを含有する水性組成物 Expired - Fee Related JP4875239B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/105,838 US6241969B1 (en) 1998-06-26 1998-06-26 Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
US09/105,838 1998-06-26
PCT/US1999/014351 WO2000000181A1 (en) 1998-06-26 1999-06-24 Aqueous compositions containing corticosteroids for nasal and pulmonary delivery

Publications (3)

Publication Number Publication Date
JP2002519318A JP2002519318A (ja) 2002-07-02
JP2002519318A5 true JP2002519318A5 (ja) 2006-08-17
JP4875239B2 JP4875239B2 (ja) 2012-02-15

Family

ID=22308060

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000556766A Expired - Fee Related JP4875239B2 (ja) 1998-06-26 1999-06-24 鼻および肺送達のためのコルチコステロイドを含有する水性組成物

Country Status (8)

Country Link
US (1) US6241969B1 (ja)
EP (1) EP1089715B8 (ja)
JP (1) JP4875239B2 (ja)
AT (1) ATE311174T1 (ja)
AU (1) AU4717199A (ja)
CA (1) CA2335900C (ja)
DE (1) DE69928665T2 (ja)
WO (1) WO2000000181A1 (ja)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4484247B2 (ja) 1995-02-24 2010-06-16 エラン ファーマ インターナショナル，リミティド ナノ粒子分散体を含有するエアロゾル
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
SE9704186D0 (sv) * 1997-11-14 1997-11-14 Astra Ab New composition of matter
US7521068B2 (en) * 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
DZ2947A1 (fr) * 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
US20020061281A1 (en) * 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US6576224B1 (en) 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
IT1313553B1 (it) * 1999-07-23 2002-09-09 Chiesi Farma Spa Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione.
FR2798290B1 (fr) 1999-09-11 2003-09-12 Glaxo Group Ltd Formulation pharmaceutique de propionate de fluticasone
WO2001047491A1 (en) * 1999-12-23 2001-07-05 Coifman Robert E Methods and formulations for the efficient delivery of water-insoluble drugs by nebulizer
US20030032632A1 (en) * 1999-12-24 2003-02-13 Crispps Leslie Alan Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate
IT1317720B1 (it) * 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
IT1317846B1 (it) 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
IT1318514B1 (it) * 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
SK286694B6 (sk) * 2000-05-22 2009-03-05 Chiesi Farmaceutici S.P.A. Aerosólový farmaceutický prostriedok
US6623765B1 (en) * 2000-08-01 2003-09-23 University Of Florida, Research Foundation, Incorporated Microemulsion and micelle systems for solubilizing drugs
US6787532B2 (en) * 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
US20030072717A1 (en) 2001-02-23 2003-04-17 Vapotronics, Inc. Inhalation device having an optimized air flow path
US20030055026A1 (en) * 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
CA2448022C (en) * 2001-05-21 2013-11-12 Injet Digital Aerosols Limited Compositions for protein delivery via the pulmonary route
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
CA2446904A1 (en) * 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
US6805853B2 (en) * 2001-11-09 2004-10-19 Alexza Molecular Delivery Corporation Delivery of diazepam through an inhalation route
US7498019B2 (en) 2001-05-24 2009-03-03 Alexza Pharmaceuticals, Inc. Delivery of compounds for the treatment of headache through an inhalation route
US6759029B2 (en) * 2001-05-24 2004-07-06 Alexza Molecular Delivery Corporation Delivery of rizatriptan and zolmitriptan through an inhalation route
US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
WO2002094218A2 (en) * 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
ES2222294T3 (es) * 2001-07-02 2005-02-01 Chiesi Farmaceutici S.P.A. Formulacion optimizada de tobramicina para administracion en forma de aerosol.
AU2002363947A1 (en) * 2001-11-21 2003-07-24 Alexza Molecular Delivery Corporation Delivery of caffeine through an inhalation route
BR0214679A (pt) * 2001-12-03 2004-12-14 Novacea Inc Composições farmacêuticas compreendendo compostos a base de vitamina d ativa
US20030178022A1 (en) * 2001-12-21 2003-09-25 Chiesi Farmaceutici S.P.A. Pressurized metered dose inhaler (PMDI) actuators and medicinal aerosol solution formulation products comprising therse actuators
US20030129242A1 (en) * 2002-01-04 2003-07-10 Bosch H. William Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
WO2003088961A1 (en) * 2002-04-19 2003-10-30 Yissum Research Development Company Of The Hebrew University Of Jerusalem Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disorders
EP1503744A1 (en) 2002-05-13 2005-02-09 Alexza Molecular Delivery Corporation Delivery of drug amines through an inhalation route
WO2003100333A2 (en) * 2002-05-21 2003-12-04 University Of Massachusetts Low pressure impact separator for separation, classification and collection of ultra­fine particles
CA2486909A1 (en) * 2002-05-23 2003-12-04 Umd, Inc. Compositions and method for transmucosal drug delivery and cryoprotection
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
WO2004004640A2 (en) * 2002-07-05 2004-01-15 Tetragrammaton Inc. Methods, compositions and kits for treating damage to excitable tissue
US20040023935A1 (en) * 2002-08-02 2004-02-05 Dey, L.P. Inhalation compositions, methods of use thereof, and process for preparation of same
US20040045546A1 (en) 2002-09-05 2004-03-11 Peirce Management, Llc Pharmaceutical delivery system for oral inhalation through nebulization consisting of inert substrate impregnated with substance (S) to be solubilized or suspended prior to use
WO2004037843A2 (en) * 2002-10-25 2004-05-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Steroid compounds comprising superoxide dismutase mimic groups and nitric oxide donor groups, and their use in the preparation of medicaments
CA2507159A1 (en) * 2002-11-26 2004-06-10 Alexza Molecular Delivery Corporation Use of loxapine and amoxapine for the manufacture of a medicament for the treatment of pain
US20040105818A1 (en) 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
JP2006514633A (ja) * 2002-11-26 2006-05-11 アレックザ ファーマシューティカルズ， インコーポレイテッド 吸入によって送達される抗精神病薬を用いた頭痛の治療
US7550133B2 (en) * 2002-11-26 2009-06-23 Alexza Pharmaceuticals, Inc. Respiratory drug condensation aerosols and methods of making and using them
US7913688B2 (en) 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
US20050026877A1 (en) * 2002-12-03 2005-02-03 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US20040109826A1 (en) * 2002-12-06 2004-06-10 Dey, L.P. Stabilized albuterol compositions and method of preparation thereof
US7879833B2 (en) * 2002-12-12 2011-02-01 Nycomed Gmbh Combination medicament
ITMI20022674A1 (it) * 2002-12-18 2004-06-19 Chiesi Farma Spa Procedimento per la preparazione di formulazioni sterili a base di principi attivi farmaceutici cristallini micronizzati da somministrare come sospensioni acquose per inalazione.
US20040208833A1 (en) * 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
TW200505500A (en) * 2003-03-31 2005-02-16 Alza Corp Non-aqueous single phase vehicles and formulations utilizing such vehicles
US9808471B2 (en) * 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
US8912174B2 (en) * 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
US7811606B2 (en) * 2003-04-16 2010-10-12 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same
CA2526475A1 (en) 2003-05-21 2004-12-02 Alexza Pharmaceuticals, Inc. Optically ignited or electrically ignited self-contained heating unit and drug-supply unit employing same
US20050020546A1 (en) * 2003-06-11 2005-01-27 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
EP1670482B2 (en) * 2003-09-16 2022-06-29 Covis Pharma B.V. Use of ciclesonide for the treatment of respiratory diseases
DE10347994A1 (de) * 2003-10-15 2005-06-16 Pari GmbH Spezialisten für effektive Inhalation Wässrige Aerosol-Zubereitung
ITMI20032054A1 (it) * 2003-10-22 2005-04-23 Monteres S R L Processo per la preparazione di sospensioni farmaceutiche da inalare.
PE20050941A1 (es) * 2003-12-16 2005-11-08 Nycomed Gmbh Suspensiones acuosas de ciclesonida para nebulizacion
WO2005065185A2 (en) * 2003-12-24 2005-07-21 Collegium Pharmaceuticals, Inc. Temperature-stable formulations, and methods of development thereof
US20070020196A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
NZ548225A (en) 2003-12-31 2012-12-21 Cydex Pharmaceuticals Inc Inhalant formulation containing sulfoakyl ether cyclodextrin and corticosteroid
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20070020298A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
US20050175679A1 (en) * 2004-02-10 2005-08-11 Michael Moshman Controlled release formulations
EP1595531A1 (en) 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
WO2005088655A1 (en) * 2004-03-12 2005-09-22 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin A magnetoresistive medium
EP1574222B1 (en) * 2004-03-12 2011-02-09 Cipla Ltd. Sterilization process for steroids
AU2005235384B2 (en) * 2004-04-20 2010-09-09 Covis Pharma B.V. Use of ciclesonide for the treatment of respiratory diseases in a smoking patient
GB0410995D0 (en) * 2004-05-17 2004-06-23 Norton Healthcare Ltd Heat sterilization of glucocorticosteroids
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
US20060045850A1 (en) * 2004-08-30 2006-03-02 Qpharma, Llc Nasal delivery of cyclodextrin complexes of anti-inflammatory steroids
US20060073173A1 (en) * 2004-10-04 2006-04-06 Maria Banach Large-scale manufacturing process for the production of pharmaceutical compositions
US20070020330A1 (en) * 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
US8758816B2 (en) * 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
WO2006058022A1 (en) * 2004-11-24 2006-06-01 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
WO2006130510A2 (en) 2005-05-27 2006-12-07 Taro Pharmaceuticals U.S.A., Inc. Stable liquid desoximethasone compositions with reduced oxidized impurity
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US20070185066A1 (en) * 2005-12-20 2007-08-09 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070160542A1 (en) * 2005-12-20 2007-07-12 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070178049A1 (en) * 2005-12-20 2007-08-02 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070249572A1 (en) * 2005-12-20 2007-10-25 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070197486A1 (en) * 2005-12-20 2007-08-23 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids
US20070178051A1 (en) * 2006-01-27 2007-08-02 Elan Pharma International, Ltd. Sterilized nanoparticulate glucocorticosteroid formulations
JP2009526858A (ja) * 2006-02-15 2009-07-23 ティカ レーケメデル アーベー コルチコステロイド溶液を製造する方法
ES2622493T3 (es) 2006-02-24 2017-07-06 Rigel Pharmaceuticals, Inc. Composiciones y métodos para la inhibición de la ruta de JAK
ES2594867T3 (es) 2007-03-09 2016-12-23 Alexza Pharmaceuticals, Inc. Unidad de calentamiento para usar en un dispositivo de administración de fármaco
FR2916974B1 (fr) * 2007-06-11 2010-11-26 Univ Angers Procede de preparation de nanoparticules lipidiques
JP5668476B2 (ja) 2007-10-08 2015-02-12 オーリニア・ファーマシューティカルズ・インコーポレイテッドＡｕｒｉｎｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． カルシニューリン阻害剤またはｍＴＯＲ阻害剤を含む眼科用組成物
US8865692B2 (en) 2007-11-13 2014-10-21 Meritage Pharma, Inc Compositions for the treatment of gastrointestinal inflammation
EP3354276B1 (en) 2007-11-13 2020-01-01 Meritage Pharma, Inc. Compositions for the treatment of gastrointestinal inflammation
BRPI0918253A2 (pt) 2008-09-12 2015-12-15 Critical Pharmaceuticals Ltd aperfeicoamento na absorcao de agentes terapeuticos atraves das membranas mucosas ou da pele
SG172885A1 (en) 2009-01-23 2011-08-29 Rigel Pharmaceuticals Inc Compositions and methods for inhibition of the jak pathway
EP2528601A1 (en) 2010-01-26 2012-12-05 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Compositions and methods for prevention and treatment of pulmonary hypertension
DK2366408T3 (da) * 2010-03-01 2012-10-22 Salvat Lab Sa Vandige, klare opløsninger af fluocinolonacetonid til behandling af inflammation i øret
US11986491B2 (en) * 2011-06-22 2024-05-21 Iview Therapeutics, Inc. Pharmaceutical compositions comprising iodine and steroid and uses thereof for sinus diseases
NZ629898A (en) 2012-03-23 2016-04-29 Oxigene Inc Compositions and methods for inhibition of cathepsins
JP2016520656A (ja) * 2013-06-03 2016-07-14 トルマー，インコーポレイティド コルチコステロイド組成物
US10111956B2 (en) 2013-06-03 2018-10-30 Tolmar, Inc. Corticosteroid compositions
EP3094355A1 (en) 2014-01-17 2016-11-23 Nephron Pharmaceuticals Corporation Budesonide cyclodextrin formulation
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
US20220000880A1 (en) 2018-11-01 2022-01-06 Rigel Pharmaceuticals, Inc. Method and composition embodiments for treating acute myeloid leukemia
US20200377518A1 (en) 2019-05-29 2020-12-03 Rigel Pharmaceuticals, Inc. Method of preventing and treating thrombosis
CN114698370A (zh) 2019-08-08 2022-07-01 里格尔药品股份有限公司 用于治疗细胞因子释放综合征的化合物和方法
WO2021030526A1 (en) 2019-08-14 2021-02-18 Rigel Pharmaceuticals, Inc. Method of blocking or ameliorating cytokine release syndrome
KR20220140711A (ko) 2020-01-13 2022-10-18 듀렉트 코퍼레이션 불순물이 감소된 지속 방출 약물 전달 시스템 및 관련 방법
AU2023237737A1 (en) 2022-03-23 2024-10-03 Rigel Pharmaceuticals, Inc. Pyrimid-2-yl-pyrazole compounds as irak inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4073943A (en) 1974-09-11 1978-02-14 Apoteksvarucentralen Vitrum Ab Method of enhancing the administration of pharmalogically active agents
DE3225706C2 (de) 1982-07-09 1984-04-26 A. Nattermann & Cie GmbH, 5000 Köln Flüssige Wirkstofformulierungen in Form von Konzentraten für Mikroemulsionen
US5192528A (en) 1985-05-22 1993-03-09 Liposome Technology, Inc. Corticosteroid inhalation treatment method
US5023271A (en) 1985-08-13 1991-06-11 California Biotechnology Inc. Pharmaceutical microemulsions
US4782047A (en) 1986-05-22 1988-11-01 Syntex Pharmaceuticals International Ltd. Aqueous steroid formulations for nasal administration
US5208226A (en) 1989-09-08 1993-05-04 Glaxo Group Limited Medicaments
US5292499A (en) 1990-09-11 1994-03-08 University Of Wales College Of Cardiff Method of preparing medical aerosol formulations including drug dissolved in reverse micelles
DE69229779T2 (de) 1991-04-19 1999-12-23 Lds Technologies, Inc. Konvertierbare mikroemulsionsverbindungen
ATE246497T1 (de) 1991-06-10 2003-08-15 Schering Corp Fluorchlorkohlenwasserstoffreie aerosolformulierungen
US5314207A (en) 1992-06-10 1994-05-24 Roadmaster Corporation Bicycle with simulated motorcycle parts
EP0656779B1 (en) 1992-08-28 2000-04-12 Pharmos Corporation Submicron emulsions as ocular drug delivery vehicles
US5478860A (en) 1993-06-04 1995-12-26 Inex Pharmaceuticals Corp. Stable microemulsions for hydrophobic compound delivery
GB9410222D0 (en) * 1994-05-21 1994-07-06 Glaxo Wellcome Australia Ltd Medicaments
JPH09157157A (ja) * 1995-12-01 1997-06-17 Pola Chem Ind Inc 医薬組成物
WO1998008490A1 (en) * 1996-09-01 1998-03-05 Pharmos Corporation Solid coprecipitates for enhanced bioavailability of lipophilic substances
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs

Similar Documents

Publication Publication Date Title
JP2002519318A5 (ja)
AU775588B2 (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
EP1671651B1 (en) Synergistic combination of pumafentrine and salmeterol
AU2003291497B2 (en) The use of an anti-allergy agent and a steroid to treat allergic rhinitis
US6297227B1 (en) Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
JP2002538110A5 (ja)
EP1915129A2 (en) Pharmaceutical formulations comprising a long-acting beta2-agonist for administration by nebulisation
WO2002094273A3 (en) Combination of an adenosine a2a-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways
CA2540174A1 (en) Aerosol formulation for inhalation, containing an anticholinergic agent
CA2425489A1 (en) Therapeutic use of aerosolized s-nitrosoglutathione in cystic fibrosis
JP2011173929A (ja) 呼吸器官の細菌性疾患の処置
JP2003527412A (ja) 安定化された乾燥粉末製剤
Boobis Comparative physicochemical and pharmacokinetic profiles of inhaled beclomethasone dipropionate and budesonide
WO2010126818A1 (en) Intranasal delivery system for dantrolene
ZA200503308B (en) New synergistic combination comprising roflumilast and formoterol
KR20030087072A (ko) 비측 투여를 위한 이미다조트리아지논 함유 조성물
JPH10500966A (ja) 経口吸入もしくは吹き込みにより投与する為の化合物、及び組成物
PL211574B1 (pl) Kompozycja farmaceutyczna zawierająca mieszankę pierwszego aktywnego składnika wybranego grupy składającej się z roflumilastu jego farmaceutycznie akceptowanych soli i N-tlenków;i drugiego aktywnego składnika wybranego z grupy składającej się z cetyryzyny i jej farmaceutycznie akceptowanych soli, zastosowanie wspomnianej kompozycji, sposób wytwarzania wspomnianej kompozycji, produkt farmaceutyczny zawierający preparaty wspomnianych składników aktywnych oraz zastosowanie wspomnianego produktu farmaceutycznego
CA2483090A1 (en) Use of therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions
JP2002527351A (ja) 気道感染に関連した風邪及びインフルエンザ様症状の予防及び治療用組成物
US4689213A (en) Method and composition for treating bronchospastic airway diseases
WO2001015777A1 (en) Pulmonary-administration of mineral ascorbates
KR20050094810A (ko) 로플루미래스트와 ｒ,ｒ-포르모테롤을 포함하는 상승작용성조합물
JP2004523536A5 (ja)
WO2008106738A1 (en) Compositions for the treatment of sexual dysfunction